Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.

Journal of immunology (Baltimore, Md. : 1950) - 15 Jan 2016

Ternant David, Arnoult Christophe, Pugnière Martine, Dhommée Christine, Drocourt Daniel, Perouzel Eric, Passot Christophe, Baroukh Nadine, Mulleman Denis, Tiraby Gérard, Watier Hervé, Paintaud Gilles, Gouilleux-Gruart Valérie

Abstract excerpt

Because IgG1 allotypes might have different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondyloarthritis patients. Infliximab was found to have a shorter half-life in patients homozygous for the G1m17,1 allotypes than in those carrying the G1m3 with no G1m1 (G1m3,-1) allotype. Because the neonatal FcR (FcRn) is involved in the pharmacokinetics of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Allotypes

Share to Immunoglobulin G

Share to Infliximab

Share to Receptors, Fc

Share to Spondylarthritis

Share to Surface Plasmon Resonance

Source

Identifiers

PMID: 26685205
DOI: 10.4049/jimmunol.1501780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.PMID 26685205Read ↗

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.Semantic proximity Read ↗

H 435‐containing immunoglobulin G 3 allotypes are transported efficiently across the human placenta: implications for alloantibody‐mediated diseases of the newbornSemantic proximity Read ↗

Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRnSemantic proximity Read ↗

Understanding Inter-Individual Variability in Monoclonal Antibody DispositionSemantic proximity Read ↗

Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.Semantic proximity Read ↗

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.Semantic proximity Read ↗

Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants.Semantic proximity Read ↗

A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.Semantic proximity Read ↗

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune diseaseSemantic proximity Read ↗

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.Semantic proximity Read ↗

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.Semantic proximity Read ↗

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.